Case report: Mesothelioma and BAP1 tumor predisposition syndrome: Implications for public health

BRCA-1 associated protein 1 (BAP1) tumour predisposition syndrome (TPDS) is a hereditary condition characterised by germline mutation of the tumour suppressor BAP1. This disorder is associated with the development of various benign and malignant tumours, mainly involving the skin, eyes, kidneys, and...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12
Main Authors Vimercati, Luigi, Cavone, Domenica, Fortarezza, Francesco, Delfino, Maria Celeste, Ficarella, Romina, Gentile, Angela, De Palma, Angela, Marulli, Giuseppe, De Maria, Luigi, Caporusso, Concetta, Marzullo, Andrea, d’Amati, Antonio, Romano, Daniele Egidio, Caputi, Antonio, Sponselli, Stefania, Serio, Gabriella, Pezzuto, Federica
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 04.08.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BRCA-1 associated protein 1 (BAP1) tumour predisposition syndrome (TPDS) is a hereditary condition characterised by germline mutation of the tumour suppressor BAP1. This disorder is associated with the development of various benign and malignant tumours, mainly involving the skin, eyes, kidneys, and mesothelium. In this article, we report the case of a man recruited through the Apulia (Southern Italy) Mesothelioma Regional Operational Centre of the National Register of Mesotheliomas, who suffered from uveal melanoma, renal cancer, and mesothelioma, and a familial cluster of BAP1 germline mutations demonstrated by molecular analyses. The family members of the proband developed multiple malignancies. As tumours arising in this context have specific peculiarities in terms of clinical behaviour, identification of this condition through appropriate genetic counselling should be considered for adequate primary, secondary, and tertiary prevention measures for offspring.
Bibliography:Edited by: Luka Brcic, Medical University of Graz, Austria
This article was submitted to Thoracic Oncology, a section of the journal Frontiers in Oncology
Reviewed by: Babak Masoomian, Tehran University of Medical Sciences, Iran; Yin Hung, Massachusetts General Hospital and Hardvard Medical School, United States
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.966063